



**First ISS-ARTOI Conference on Integrative Oncology
Fifth ARTOI International Congress**

*Medicina traslazionale: dal laboratorio all'evidenza clinica
Translational medicine: from the Laboratory to Clinical Evidence*

Organizzato da

ISTITUTO SUPERIORE DI SANITA'

Department of Hematology, Oncology and Molecular Medicine
Department of Infectious, Parasitic and Immune-Mediated Diseases
Department of Technology and Health
Department of Therapeutic Research and Medicine Evaluation

ARTOI

Research Association for Integrative Oncology

Roma, 6-7 novembre 2013

**Istituto Superiore di Sanità
Aula Pocchiari**



Origine della manifestazione. Durante il congresso si presenteranno e discuteranno aspetti scientifici relativi alle terapie oncologiche "integrate". Per oncologia integrata si intende l'applicazione combinata di una serie di metodiche siano esse interventistiche (chirurgia, radioterapia, ipertermia), che farmacologiche (chemioterapia, immunoterapia, supporto complementare), che dietetiche e psicologiche, atte a migliorare lo stato psicofisico, la qualità della vita del paziente e la maggior probabilità di risposte positive. Le terapie oncologiche "integrate" oggi nel mondo sono considerate necessarie nella gestione del paziente neoplastico, ai fini del miglioramento delle cure e della qualità di vita. Le terapie oncologiche più costose non sempre si sono rivelate le più efficienti. I risultati ottenuti con l'impiego delle terapie oncologiche integrate in alcuni casi hanno favorito l'ottimizzazione della terapia associata ad una soddisfacente riduzione dei costi per il SSN.

Razionale. In this Conference scientific aspects of integrative cancer therapies will be presented and discussed. Integrative oncology addresses the combined application of interventional (surgery, radiation, hyperthermia), pharmacological (chemotherapy, immunotherapy, complementary support), dietary and psychological methods. The integrative approach aims to improve the physical and mental health-related quality of life in patients, thus increasing the probability of treatment success. All over the world today, integrative cancer therapies are deemed necessary to meet cancer patients' needs. The most expensive cancer therapies have not always proved to be the most effective. The results obtained with the use of integrative cancer therapies have favoured, in some cases, the optimization of the associated therapy with a satisfactory reduction of costs for the NHS.

Scopo e obiettivi. Scopo primario di questo convegno è quello di dedicare due giornate allo studio, alla ricerca ed all'applicazione di trattamenti oncologici effettuati attraverso l'uso integrato di più opzioni terapeutiche. Questo congresso permetterà di acquisire conoscenze nei campi (i) della prevenzione dei tumori, con particolare riferimento alla nutrizione, al sistema immunitario e al microbiota; (ii) della ricerca relativa all'uso di nuove molecole, di diverse vie o metodiche di somministrazione dei farmaci, o di integrazione fra varie metodiche di trattamento, di farmaci o molecole; (iii) dei risultati ottenuti in clinica mediante l'applicazione di trattamenti oncologici attraverso l'uso integrato di più opzioni terapeutiche.

Aims. The primary aim of this conference is to devote two days to the study, the research and the application of cancer treatments based on the integrative use of multiple therapeutic options. Conference participants will gain knowledge in: i) cancer prevention, with particular regard to nutrition, immune system and microbiome; ii) research on the use of new molecules, implementation of new methods of drug administration, and integration of different treatment methods; iii) results obtained in preclinical and clinical studies on the administration of cancer treatments through the integrative use of different therapeutic options.



CONFERENCE PROGRAM

Wednesday, November 6

- 9.00 Registration
- 9.30 Opening Ceremony
Fabrizio Oleari, President - Istituto Superiore di Sanità
Massimo Bonucci, President – Associazione Ricerca Terapie Oncologiche Integrate
Pietro Bartolini, Acting Director - Department of Technology and Health, Istituto Superiore di Sanità
Filippo Belardelli, Director - Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità
Giovanni Rezza, Director - Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità
Stefano Vella, Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità

CANCER PREVENTION

Chairs: Carla Fiorentini, Stephan Sagar

Keynote Lecture

10.00 **Philip A. Salem** The dynamics of the multidisciplinary approach in cancer treatment

10.30 *Coffee break*

11.00 **Ettore Bergamini** Diet restriction and cancer

11.20 **Marco Candela** Diet, intestinal microbiome and colorectal cancer onset

11.40 **Gianluca Pazzaglia** Pap-breast: innovative method for prevention of breast cancer

12.00 **Massimo D'Archivio** Dietary fatty acid and adipose tissue function in colon cancer

12.20 *Discussion*

13.00 *Lunch and poster session*

INTEGRATIVE ONCOLOGY RESEARCH

Chairs: Giampiero Ravagnan, Filippo Belardelli

14.30 **Bharat B Aggarwal** Multi-targeting of multigenic cancer by nutraceuticals: role in prevention and treatment

14.50 **Stefania Meschini** Natural alkaloid products: drug discovery and therapeutic optimization

15.10 **Francesca Mondello** Potential therapeutic activity of tea tree oil and its main component, terpinen-4-ol, against mucocutaneous candidosis in oncological patients.

15.30 **Annarita Stringaro** Antitumor activity of aloe-emodin in breast cancer cells

15.50 *Discussion*



16.10 *Coffee break and poster session*

16.30 **Pantaleo Romanelli** The frontiers of radiosurgery. From the CyberKnife to Synchrotron

16.55 **Giuseppe Novelli** Oncogenomics and personalized medicine

17.15 *Discussion*

19.30 **Gala Dinner**

Thursday, November 7

INTEGRATIVE THERAPY IN ONCOLOGY

Chairs: Massimo Fioranelli, Stefano Vella

9.00 **Gary E. Deng** Acupuncture in cancer care: the US experience

9.20 **Eran Ben-Arye** Integrative medicine approach to palliative care improvement

9.40 **Matteo Caleo** The bacterial protein toxin CNF1 prolongs survival in a mouse model of glioma

10.00 *Discussion*

10.30 *Coffee break*

11.00 **Stephan Sagar** Patient-centred integrative care: what are the challenges?

11.20 **Fabio Firenzuoli** Natural products and drug vigilance

11.40 **Enrico Proietti** Novel strategies for combining immunotherapy with chemotherapy: from the preclinical studies to the clinical experimentation

12.00 *Discussion*

12.30 *Lunch and poster session*

INTEGRATIVE APPROACH TO CANCER CARE: CASE STUDIES

Chairs: Giuseppe Di Fede, Giovanni Rezza

14.00 **Dana Flavin** Nanoparticle-mediated delivery: crossing intracellular and cellular barriers

14.15 **Jürgen-Johannes Kuehn** Integrative treatments in cancer patients: clinical research on mistletoe and cancer: personal experience

14.25 **Giuseppe Lupi** Acupuncture as a complementary therapy for chemotherapy side effects: the experience of a Public Health Service in Aosta Valley Autonomous Region

14.35 **Philip A. Salem** The Salem's program cancer treatment: multidisciplinary approach

14.50 **Franco Desiderio** Treatment of menopausal symptoms in cancer breast disease free patients: clinical trial randomized double-blind

15.00 **Gary Deng** Integrative acupuncture in cancer patients: personal cases

15.15 **Massimo Bonucci/Carlo Pastore** Integrative treatments in cancer patients: case studies

15.30 **Elio Rossi** Homeopathy and nutrition in Oncology: experience of homeopathy Outpatient clinic - Regional structure of reference USL 2 Lucca

15.40 **Best Contributed Poster presentations**

15.50 **Alfredo Pelli** The digital medical record and videoconference for the patient: just a click away for integrative consulting.

16.00 **Mauro Grigioni** Care models and Information and Communication Technology in favour of long-term survivors

16.15 *Closing remarks*



Relatori e Moderatori *Chairpersons and Speakers*

- Bharat B. Aggarwal**, Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX, USA
- Eran Ben Arye**, Integrative Oncology Program Lin Medical Center, Technion-Israel Institute of Technology, Israel
- Filippo Belardelli**, Department of Hematology, Oncology and Molecular Medicine, ISS, Rome, Italy
- Ettore Bergamini**, Research Center for Aging Biology and Pathology, University of Pisa, Italy
- Massimo Bonucci**, President of ARTOI, Rome, Italy
- Marco Candela**, Department of Pharmaceutical Sciences, University of Bologna, Italy
- Matteo Caleo**, CNR Neuroscience Institute, Pisa, Italy
- Massimo D'Archivio**, Department of Food Safety and Veterinary Public Health, ISS, Rome
- Gary E. Deng**, Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, NY, US.
- Franco Desiderio**, Department of Oncology, "Ospedale degli Infermi", Rimini, Italy
- Giuseppe Di Fele**, Institute of Biological Medicine, Milan, Italy
- Massimo Fioranelli**, Life Science Study Center, G. Marconi University, Rome, Italy
- Carla Fiorentini**, Department of Therapeutic Research and Medicine Evaluation, ISS, Rome, Italy
- Fabio Firenzuoli**, Integrative Medicine Center, University of Florence, Italy
- Dana Flavin**, Founding Director of Collaborative Medicine & Research Washington D.C - U.S.A.
- Mauro Grigioni**, Department of Technology and Health, ISS, Rome, Italy
- Jürgen-Johannes Kuehn**, Centre of Integrative Oncology and Supportive Care, Arlesheim, Switzerland
- Giuseppe Lupi**, Acupuncture School CSTNF, Turin, Italy
- Stefania Meschini**, Department of Technology and Health, ISS, Rome, Italy
- Francesca Mondello**, Department of Infectious, Parasitic and Immune-Mediated Diseases, ISS, Rome, Italy
- Giuseppe Novelli**, Medical Genetic Laboratory, Tor Vergata University, Rome, Italy
- Carlo Pastore**, Department of Oncology, Villa Salaria Hospital, Rome, Italy
- Gianluca Pazzaglia**, Breast Clinic Center, Perugia, Italy
- Alfredo Pelli**, Head of Viversano.com.
- Enrico Proietti**, Department of Hematology, Oncology and Molecular Medicine, ISS, Rome, Italy
- Giampiero Ravagnan**, Microbiology, Cà Foscari University, Venice, Italy
- Giovanni Rezza**, Department of Infectious, Parasitic and Immune-Mediated Diseases, ISS, Rome, Italy
- Pantaleo Romanelli**, Cyberknife Center, Centro Diagnostico Italiano (CDI), Milan, Italy, and European Synchrotron Radiation Facility, Grenoble, France
- Elio Rossi**, Chief of the Homeopathy Division, Local Health Unit 2, Lucca, Italy
- Stephan Sagar**, Department of Oncology, McMaster University, Hamilton, Ontario L8S 4L8, Canada
- Philip A. Salem**, Emeritus Director Cancer Research Program St. Luke's Episcopal Hospital, Houston, U.S.A.
- Annarita Stringaro**, Department of Technology and Health, ISS, Rome, Italy
- Stefano Vella**, Department of Therapeutic Research and Medicine Evaluation, ISS, Rome, Italy

Comitato Scientifico *Scientific Advisory Board*

- Fabrizio Oleari**, President - Istituto Superiore di Sanità
- Pietro Bartolini**, Acting Director - Department of Technology and Health, ISS
- Filippo Belardelli**, Director - Department of Hematology, Oncology and Molecular Medicine, ISS
- Giovanni Rezza**, Director - Department of Infectious, Parasitic and Immune-Mediated Diseases, ISS
- Stefano Vella**, Director - Department of Therapeutic Research and Medicine Evaluation, ISS
- Massimo Bonucci**, President - ARTOI, Research Association for Integrative Oncology, Rome, Italy



Segreteria Scientifica Congress Coordinators

Massimo Bonucci, President of ARTOI, Rome, Italy
Andrea Del Buono, President of “Academy of Micronutrition Linus Pauling”, Caserta, Italy
Giuseppe Di Fede, Director Institute of Biological Medicine, Milan, Italy
Massimo Fioranelli, Life Science Study Center, G. Marconi University, Rome, Italy
Carla Fiorentini, Department of Therapeutic Research and Medicine Evaluation, ISS, Rome, Italy
Andrea Geraci, Department of Therapeutic Research and Medicine Evaluation, ISS, Rome, Italy
Vezia Mei, Consultant, Villa Anna Maria Hospital, Rome, Italy
Stefania Meschini, Department of Technology and Health, ISS, Rome, Italy
Agnese Molinari, Department of Technology and Health, ISS, Rome, Italy
Francesca Mondello, Department of Infectious, Parasitic and Immune-Mediated Diseases, ISS, Rome, Italy
Annarita Stringaro, Department of Technology and Health, ISS, Rome, Italy

Segreteria Organizzativa Organizing Secretariat

Mosti Federica

ARTOI
Via del Podere di San Giusto, 83 - 00166 Roma
Telefono: +393381074337
segreteria@artoi.it

Maria Letizia Bertollini

ARTOI
Via del Podere di San Giusto, 83 - 00166 Roma
Tel: +393383649983
segreteria@artoi.it

Monica Brocco

Department of Technology and Health, ISS, Rome, Italy
Tel: 06 4990 6216
monica.brocco@iss.it

Daniela Casale

Department of Infectious, Parasitic and Immune-Mediated Diseases, ISS, Rome, Italy
Telefono: 06 4990 3225
daniela.casale@iss.it

Rossella Di Nallo

Department of Therapeutic Research and Medicine Evaluation, ISS, Rome, Italy
Telefono: 06 4990 3327
rossella.dinallo@iss.it

Veronica Michetti

Department of Hematology, Oncology and Molecular Medicine, ISS, Rome, Italy
Telefono: 06 4990 6094
veronica.michetti@iss.it



INFORMAZIONI GENERALI - GENERAL INFORMATION

SEDE – CONFERENCE VENUE

Istituto Superiore di Sanità, Aula Pocchiari
Viale Regina Elena 299, Roma

DESTINATARI – TARGET AUDIENCE

Medici, biologi, farmacisti, naturopati, operatori del Servizio Sanitario Nazionale, studenti
Physicians, pharmacists, naturopaths, National Health Service professionals, students

POSTI DISPONIBILI - MAXIMUM NUMBER OF ATTENDANTS: 200

MODALITA' DI ISCRIZIONE E DEADLINE - REGISTRATION & DEADLINE

La domanda, compilata in tutte le sue parti, deve essere stampata, firmata e inviata alla Segreteria Organizzativa via fax (+39 06 6649 5653) o per email (segreteria@artoi.it) entro il **25 ottobre 2013**.

Please fill in this application form, print it out, sign it and send it to the Organizing secretariat by fax (+39 06 6649 5653) or by mail (segreteria@artoi.it) by **October 25th, 2013**.

QUOTA D'ISCRIZIONE - REGISTRATION FEES

- 120 euro**
- 90 euro** (Soci ARTOI - **ARTOI members**)
- 50 euro** (Studenti, personale non strutturato - **Students, temporary workers**)

La quota d'iscrizione include: Kit congressuale, Libro degli Abstract, due pranzi, tre coffe-breaks
The registration fee includes: Congress kit, Book of Abstracts, two lunches, three coffee breaks

MODALITA' DI PAGAMENTO – PAYMENT METHODS

- Bonifico bancario – **Bank transfer** ARTOI – Monte dei Paschi c/o Ag. 16 - Piazza Giureconsulti, Roma – **BIC**: PASCITM1R16 - c.c.: 20804.49 - **IBAN**: IT 67 H 01030 03216 000002080449
- Carta di credito – **Credit card** PAYPAL on-line at <http://www.artoi.it/>

LINGUA UFFICIALE – OFFICIAL LANGUAGE

La lingua ufficiale della Conferenza è l'**italiano**. E' prevista la **traduzione simultanea in inglese**.
The official language of the Conference will be **Italian**, with simultaneous **Italian-English translation**.



ABSTRACT PER LA SESSIONE POSTER

Modulo e istruzioni per la stesura dell'abstract. Si possono scaricare da www.ARTOI.it

Deadline per l'invio degli abstract. Inviare a stefania.meschini@iss.it e a annarita.stringaro@iss.it entro il **20 settembre 2013**

Notificazione dell'accettazione degli abstract: 7 ottobre 2013

Se l'abstract verrà accettato, almeno uno degli autori dovrà registrarsi per partecipare alla Conferenza. Tutti gli abstract accettati saranno pubblicati nel Libro degli Abstract. Saranno scelti i due poster migliori per la presentazione orale in aula.

ABSTRACTS FOR THE POSTER SESSION

Abstract Form and Guidelines. Download from www.ARTOI.it

Abstract Submission Deadline. Send the Abstract to stefania.meschini@iss.it and to annarita.stringaro@iss.it within **20 September 2013**

Notification of Abstract Acceptance: 7 October 2013

If an abstract is accepted for presentation, at least one author must pay the registration fee to attend the Conference. All accepted abstracts will be published in the Abstract Book. The two best contributed abstracts will be selected for oral presentation.

ACCREDITAMENTO ECM

Non è previsto l'accREDITAMENTO ECM.

ATTESTATI – CERTIFICATE OF ATTENDANCE

Al termine della manifestazione, sarà rilasciato un attestato di partecipazione.

At the end of the Conference participants will receive a Certificate of Attendance.

INFORMAZIONI. INFORMATION

<http://www.artoi.it>

Per ogni informazione attinente alla manifestazione, si prega di contattare: segreteria@artoi.it

For any further information about the conference, please contact segreteria@artoi.it

Manifestazione supportata da contributo non vincolante di:

With the unconditional support of:

International Biolife srl; Imgep srl (Istituto di medicina genetica personalizzata); Imbio srl (Istituto di Medicina Biologica); Natur srl; Allgeco Società consortile per Azioni; Diapath S.p.A.; Biogroup srl; CredSec S.p.A.; Ghimas S.p.A.; Andromedic srl; Weleda Italia srl; Coop Scia Servizi Cure integrate avanzate; Eurodream srl; Villa Annamaria srl; Eye Tech srl; Mediterranea Servizi globali sas (Santa Candida grano Khorasan); OH Int.Le srl; Farmacia Arrigoni; Farmacia Madre del Buon Consiglio dott. Massimo Romiti; Bio Farmex srl; Associazione Amici di Carlo Onlus.